Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Helmut Glantschnig

Shun-ichi Harada

Viera Kasparcova

Zhiqiang An

Fubao Wang

Fang Chen

John E Fisher

Donald B Kimmel

Alfred A Reszka

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Antibodies specific for Dkk-1

The present invention provides rhesus monkey dickkopf-1 (rhDkk-1) and nucleotide sequences encoding it. Also provided herein are recombinant vectors, and recombinant hosts comprising rhDkk-1-encoding nucleotide sequences. Isolated rhDkk-1 can be used to screen and identify novel osteoanabolic compounds that stimulate bone formation for the treatment of osteoporosis or other disorders characterized by insufficient bone mass.

Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof

The cynomolgus monkey Dickkopf-4 (cDkk-4) protein, isolated nucleic acid molecules which encode the cDkk-4 protein, and recombinant vectors and hosts comprising DNA encoding the cDkk-4 protein are disclosed. Also disclosed are methods for identifying analytes which interfere with the interaction between the cDkk-4 protein and a homologous or heterologous Dkk receptor and analytes which interfere with the interaction and stimulate bone formation. Analytes identified using the methods are useful for treating osteoporosis and other bone loss disorders.

Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof

Growing community of inventors

Schwenksville, PA, United States of America

Helmut Glantschnig